Magnesium Alloy Stent Coating for pH Neutral Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Magnesium alloy stents degrade too rapidly in vivo, and their alkaline degradation products accelerate corrosion, leading to premature loss of mechanical strength and potential tissue burden, with challenges in controlling degradation time and maintaining pH neutrality.
Innovation Solution
A biodegradable metallic stent with a coating blend of high and low molecular weight polylactides or polylactide-co-glycolides, which generates acid to neutralize alkaline degradation products and control degradation, maintaining mechanical strength and pH neutrality, and optionally incorporating therapeutic agents for sustained release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If magnesium alloy is used as stent material, then biodegradability is achieved, but degradation rate is too rapid and cannot be controlled
Solution Approach 1:
The patent applies composite materials by combining magnesium alloy with polymer coatings (polylactide, polylactide-co-glycolide, or polydioxanone) to create a multi-layered structure. The polymer coating acts as a barrier that controls the degradation rate of the magnesium alloy core, allowing the stent to maintain mechanical strength for the required duration while eventually degrading in a controlled manner.
Solution Approach 2:
The patent utilizes parameter changes by adjusting the thickness of the polymer coating to control the degradation rate. By varying the coating thickness parameter, the degradation time can be tuned to match the required mechanical support duration, thereby resolving the contradiction between rapid degradation and controlled degradation timeline.
2Duration of action of moving object
If magnesium alloy degrades in vivo, then biodegradability is achieved, but local pH increases and accelerates corrosion
Solution Approach 1:
The patent introduces an intermediary buffer layer (polymer coating) between the magnesium alloy and the physiological environment. This intermediary layer moderates the interaction by controlling the release of alkaline degradation products, preventing sudden pH spikes that would accelerate corrosion. The buffer layer acts as a mediator that slows down the degradation process and maintains pH stability.
Solution Approach 2:
The patent converts the harmful alkaline degradation products into a beneficial controlled-release mechanism. By designing the polymer coating to degrade at a controlled rate, the alkaline products are released gradually rather than all at once, transforming the harmful rapid corrosion effect into a beneficial sustained degradation profile that maintains mechanical integrity longer.
3Duration of action of moving object
If polymer coating is applied to control degradation, then degradation rate is reduced, but coating uniformity and complexity increase
Solution Approach 1:
The patent employs thin film polymer coatings applied through dip-coating or spray-coating techniques. These flexible thin films provide effective degradation control with minimal added complexity. The thin film structure maintains stent flexibility while providing the necessary barrier function to control magnesium alloy degradation.
Solution Approach 2:
The patent simplifies the coating structure by focusing on controlling a single critical parameter - the coating thickness. By optimizing this one parameter, the patent achieves effective degradation control without requiring complex multi-layer structures or additional functional components, thereby minimizing device complexity while maintaining degradation control efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stent achieves controlled degradation and prolonged mechanical strength, reducing tissue burden and enhancing drug efficacy by maintaining a neutral pH environment, allowing for optimal vascular remodeling and drug delivery.
Implementation Method 1
the at least one coating comprising of a blend of a polylactide having a molecular weight of at least one hundred kilodaltons and a polylactide having a molecular weight of less than ten kilodaltons
Implementation Method 2
a coating for sustained release of agents to control the degradation rate
Data Source
AI summary
A biocompatible metallic material may be configured into any number of implantable medical devices, including intraluminal stents. The biocompatible metallic material may comprise a magnesium alloy. The magnesium alloy implantable medical device may be designed to degrade over a given period of time. In order to control the degradation time, the device may be coated or otherwise have affixed thereto one or more coatings, one of which comprises a material for controlling the degradation time and maintain a pH neutral environment proximate the device. Additionally, therapeutic agents may be incorporated into one or more of the coatings on the implantable medical device.